Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 37
Filter
1.
J Dtsch Dermatol Ges ; 20(9): 1274-1275, 2022 09.
Article in English | MEDLINE | ID: mdl-36162028
2.
J Dtsch Dermatol Ges ; 16(5): 543-557, 2018 May.
Article in English | MEDLINE | ID: mdl-29726638

ABSTRACT

Accepted by the WHO and EORTC as a variant of classic mycosis fungoides, folliculotropic (syn.: follicular or pilotropic) mycosis fungoides (FMF) is characterized by a broad clinical and histological spectrum with numerous differential diagnoses. Recent studies have shown that FMF can be divided into two prognostically different subgroups, both marked by histological as well as clinical differences. Treatment should therefore be tailored to the various subtypes and clinical courses. The present review highlights the clinical and histological manifestations of FMF as well as the new subclassification. Moreover, important differential diagnoses and therapeutic options are discussed.


Subject(s)
Mycosis Fungoides , Diagnosis, Differential , Humans , Mycosis Fungoides/diagnosis , Mycosis Fungoides/pathology , Prognosis
3.
5.
Eur J Dermatol ; 20(5): 575-9, 2010.
Article in English | MEDLINE | ID: mdl-20605766

ABSTRACT

BRAF exon 15 mutations have been identified in a large proportion of malignant melanomas, melanoma metastases and melanocytic nevi. Mutated BRAF is one of the potential activators of the mitogen-activated protein kinase (MAPK) signaling pathway by phosphorylating ERK (extracellular signal-regulated kinase). We therefore analyzed the correlation of BRAF V600E and ERK-activation in 20 malignant melanomas and 21 subsequently evolved, paired metastases of the same donor by BRAF exon 15 DNA sequencing and phospho-specific immunohistochemistry for ERK. Phospho-ERK expression was present in 84% of primary melanomas and in all 19 metastases analyzed. In contrast, BRAF mutational status was concordant in only 12/20 pairs (60%) of the primary melanoma and metastasis of the same patient. Surprisingly, the BRAF mutation did not correlate with pERK expression. As even single tumors showed heterogeneous staining for pERK, we used laser-capture microdissection to study BRAF V600E status in pERK positive and pERK negative cells separately. Even on the single cell level ERK activation did not correlate with the BRAF mutation. Our results demonstrate that, in melanomas, activation of the MAPK pathway can occur through signaling pathways operating independently of BRAF T1799A.


Subject(s)
Extracellular Signal-Regulated MAP Kinases/metabolism , Melanoma/genetics , Melanoma/metabolism , Proto-Oncogene Proteins B-raf/genetics , Skin Neoplasms/genetics , Skin Neoplasms/metabolism , Cell Line, Tumor , Humans , Melanoma/secondary , Microdissection , Paraffin Embedding , Phosphorylation , Skin Neoplasms/pathology
6.
Am J Dermatopathol ; 32(6): 593-8, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20534985

ABSTRACT

Several groups confirmed Merkel cell polyomavirus (MCPyV) as the likely causative agent of Merkel cell carcinoma. Hematolymphoid disorders are known to be a substantial risk factor for Merkel cell carcinoma, and vice versa. The association between MCPyV and hematologic neoplasms is poorly analyzed, as well as the speculation that lymphocytes may serve as reservoir for MCPyV. Therefore, we investigated the prevalence of MCPyV DNA in primary cutaneous T- and B-cell lymphomas, pseudolymphomas (PLs), and inflammatory skin diseases with dominant lymphocytic infiltrate. We performed a molecular pathology study in 22 tissue samples and 1 blood sample of different cutaneous lymphomas from 19 patients (17 mature T-cell neoplasms, 5 mature B-cell neoplasms, and 1 immature hematopoietic malignancy), 13 PLs from 12 patients, and 25 various inflammatory skin diseases from 23 patients. All tumors were analyzed for the presence of MCPyV DNA by polymerase chain reaction, confirmed by Southern blot hybridization of polymerase chain reaction products. We detected MCPyV DNA in 4 of 23 (17.4%) cutaneous lymphoma tissue samples (3 of 17 mature T-cell neoplasms and 1 of 5 mature B-cell neoplasms), in 2 of 13 (15.4%) PL tissue samples, and 2 of 25 (8%) inflammatory skin conditions (1 drug reaction and 1 erythema multiforme). We conclude that MCPyV DNA is infrequently, but consistently present in lesional tissue from patients with primary cutaneous lymphomas, PLs, and inflammatory skin diseases; prevalence is in the range of 8%-17%. Our results suggest that MCPyV does not play a significant role in the pathogenesis of cutaneous lymphoproliferative disorders.


Subject(s)
Lymphoma/pathology , Polyomavirus Infections/pathology , Pseudolymphoma/pathology , Skin Neoplasms/pathology , Tumor Virus Infections/pathology , Adult , Aged , Aged, 80 and over , DNA, Viral/analysis , Female , Humans , Lymphoma/virology , Male , Middle Aged , Polyomavirus/isolation & purification , Polyomavirus Infections/complications , Pseudolymphoma/virology , Skin Neoplasms/virology , Tumor Virus Infections/complications , Young Adult
7.
Histopathology ; 56(1): 57-70, 2010 Jan.
Article in English | MEDLINE | ID: mdl-20055905

ABSTRACT

This review focuses on the evolution and conceptual aspects of classifications for cutaneous lymphomas. The World Health Organization/European Organization for Research and Treatment of Cancer (WHO/EORTC) classification and the WHO classification (4th edn, 2008) represent the first widely accepted classifications for lymphomas, in which the complete spectrum of primary cutaneous lymphomas is included. These classifications for primary cutaneous lymphomas define disease entities with distinct clinical, histological, immunophenotypic and genetic features. Final diagnosis is based on a synoptic integration of these features and implies clinicopathological correlation as a pivotal element of the diagnostic approach for primary cutaneous lymphomas. The entities, their definitions and diagnostic criteria of cutaneous lymphomas listed in the WHO/EORTC and WHO classifications are presented. Recent changes in the terminology and staging, practical implications and future perspectives are discussed.


Subject(s)
Lymphoma/classification , Skin Neoplasms/classification , Humans , Lymphoma/pathology , Skin Neoplasms/pathology , World Health Organization
8.
J Dtsch Dermatol Ges ; 8(5): 341-6, 2010 May.
Article in English, German | MEDLINE | ID: mdl-19845819

ABSTRACT

BACKGROUND: With an incidence of 1.5-1.8/1 million inhabitants per year, toxic epidermal necrolysis is a rare but life threatening disease. It is almost always drug-induced and its lethality is pronounced with up to 50 %. Several therapeutic options are described in literature; however, there is still lack of a universally accepted and specific therapy of toxic epidermal necrolysis. METHODS: This survey considers 8 cases of toxic epidermal necrolysis diagnosed and treated in our clinic from 2003 to 2007. The epidermal sloughing was > 30 % of the body surface in each case. RESULTS: After immediately discontinuing the drug suspected of being responsible for toxic epidermal necrolysis, we treated with systemic corticosteroids in an initial dose of up to 1.5 mg/kg. Moreover, special emphasis was put on basic measures such as control of vital parameters. With this treatment we reached good results; none of the patients died. conclusions: Immediate beginning of therapy is essential for a successful treatment of toxic epidermal necrolysis. Besides systemic therapy with corticosteroids, certain basic measures such as isolation of patients at adequate room temperature to prevent hypothermia, strict control of circulation, temperature and laboratory parameters, daily smears of skin and mucous membranes and a diet rich in calories due to the catabolic metabolic status are very important for successful outcome.


Subject(s)
Prednisone/therapeutic use , Stevens-Johnson Syndrome/drug therapy , Adult , Aged , Aged, 80 and over , Allopurinol/therapeutic use , Allopurinol/toxicity , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/toxicity , Anti-Inflammatory Agents/therapeutic use , Anticonvulsants/therapeutic use , Anticonvulsants/toxicity , Bacterial Infections/diagnosis , Bacterial Infections/drug therapy , Bacterial Infections/mortality , Ciprofloxacin/therapeutic use , Ciprofloxacin/toxicity , Drug Combinations , Female , Folic Acid/therapeutic use , Folic Acid/toxicity , Gout Suppressants/therapeutic use , Gout Suppressants/toxicity , Humans , Hydroxocobalamin/therapeutic use , Hydroxocobalamin/toxicity , Lidocaine/therapeutic use , Lidocaine/toxicity , Male , Middle Aged , Phenytoin/therapeutic use , Phenytoin/toxicity , Pyridoxine/therapeutic use , Pyridoxine/toxicity , Stevens-Johnson Syndrome/diagnosis , Stevens-Johnson Syndrome/mortality , Superinfection/diagnosis , Superinfection/drug therapy , Superinfection/mortality , Survival Rate , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use , Trimethoprim, Sulfamethoxazole Drug Combination/toxicity
9.
J Cutan Pathol ; 37(1): 28-34, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19615033

ABSTRACT

BACKGROUND: Merkel cell polyomavirus (MCPyV) is the likely causative agent of Merkel cell carcinoma (MCC). However, the prevalence of MCPyV in non-MCC population and its possible role in the pathogenesis of other skin cancers are not known yet. METHODS: A molecular pathology study was performed in 33 MCC samples and 33 age- and sex-matched samples of sun exposed non-MCC tumors [12 seborrheic keratoses (SK), 11 basal cell carcinomas (BCC) and 10 lentigo maligna melanomas (LMM)]. All tumors were analyzed for presence of MCPyV-DNA by polymerase chain reaction (PCR) and Southern-Blot hybridization of PCR products. RESULTS: MCPyV sequences were detected in 21 MCC samples (64%) and in 2 non-MCC tumors of sun exposed skin (6%; both SK-patients). Neither the tissue samples from BCC nor LMM proved positive for MCPyV sequences. CONCLUSION: We were able to confirm prior data on prevalence of MCPyV-DNA in MCC. Furthermore, a female predominance of MCPyV-positive MCC-patients was detected. There was no relevant association of MCPyV with SK, BCC and LMM. Speculative, prevalence of MCPyV in an age- and sex-matched non-MCC population could average up to 6%.


Subject(s)
Carcinoma, Merkel Cell/virology , Hutchinson's Melanotic Freckle/virology , Neoplasms, Basal Cell/virology , Polyomavirus Infections/complications , Polyomavirus/isolation & purification , Skin Neoplasms/virology , Adult , Aged , Aged, 80 and over , Antigens, Viral, Tumor/analysis , Carcinoma, Merkel Cell/epidemiology , Carcinoma, Merkel Cell/pathology , Comorbidity , DNA, Neoplasm/analysis , DNA, Viral/analysis , Female , Germany/epidemiology , Humans , Hutchinson's Melanotic Freckle/pathology , Keratosis, Seborrheic/pathology , Keratosis, Seborrheic/virology , Male , Middle Aged , Neoplasms, Basal Cell/pathology , Polyomavirus/genetics , Polyomavirus/immunology , Polyomavirus Infections/epidemiology , Polyomavirus Infections/pathology , Sex Factors , Skin/pathology , Skin/virology , Skin Aging , Skin Neoplasms/epidemiology , Skin Neoplasms/pathology
11.
J Dtsch Dermatol Ges ; 7(12): 1065-7, 2009 Dec.
Article in English, German | MEDLINE | ID: mdl-19694889

ABSTRACT

Only 40 cases of primary cutaneous gamma/delta T-cell lymphoma (GD-TCL) have been described. GD-TCL was included as a provisional entity in the WHO-EORTC classification of cutaneous lymphomas in 2005. GD-TCL often failed to respond to polychemotherapy and radiation therapy and have a poor prognosis with a mean survival of only 15 months. We present a patient treated with surgery, immunomodulatory therapy, and polychemotherapy. He then received hematopoietic stem cell transplantation and has been in complete remission since. Allogeneic stem cell transplantation appears to be a promising therapeutic option for aggressive and generally fatal lymphomas like GD-TCL.


Subject(s)
Lymphoma, T-Cell, Cutaneous/pathology , Lymphoma, T-Cell, Cutaneous/surgery , Skin Neoplasms/pathology , Skin Neoplasms/surgery , Stem Cell Transplantation , Adult , Humans , Lymphoma, T-Cell, Cutaneous/genetics , Male , Receptors, Antigen, T-Cell, gamma-delta/genetics , Skin Neoplasms/genetics , Treatment Outcome
12.
Blood ; 114(8): 1696-706, 2009 Aug 20.
Article in English | MEDLINE | ID: mdl-19546478

ABSTRACT

Signaling through tumor necrosis factor receptor 1 (TNFR1) controls bacterial infections and the induction of inflammatory Th1 cell-mediated autoimmune diseases. By dissecting Th1 cell-mediated delayed-type hypersensitivity responses (DTHRs) into single steps, we localized a central defect to the missing TNFR1 expression by endothelial cells (ECs). Adoptive transfer and mast cell knockin experiments into Kit(W)/Kit(W-v), TNF(-/-), and TNFR1(-/-) mice showed that the signaling defect exclusively affects mast cell-EC interactions but not T cells or antigen-presenting cells. As a consequence, TNFR1(-/-) mice had strongly reduced mRNA and protein expression of P-selectin, E-selectin, ICAM-1, and VCAM-1 during DTHR elicitation. In consequence, intravital fluorescence microscopy revealed up to 80% reduction of leukocyte rolling and firm adhesion in TNFR1(-/-) mice. As substitution of TNF(-/-) mice with TNF-producing mast cells fully restored DTHR in these mice, signaling of mast cell-derived TNF through TNFR1-expressing ECs is essential for the recruitment of leukocytes into sites of inflammation.


Subject(s)
Endothelium, Vascular/pathology , Inflammation/etiology , Mast Cells/physiology , Receptor Cross-Talk/physiology , Receptors, Tumor Necrosis Factor, Type I/metabolism , Tumor Necrosis Factor-alpha/metabolism , Animals , Cell Adhesion Molecules/genetics , Cell Adhesion Molecules/metabolism , Cells, Cultured , Endothelium, Vascular/immunology , Endothelium, Vascular/metabolism , Haptens/adverse effects , Hypersensitivity, Delayed/chemically induced , Hypersensitivity, Delayed/genetics , Hypersensitivity, Delayed/immunology , Inflammation/genetics , Inflammation/metabolism , Mast Cells/immunology , Mast Cells/metabolism , Mice , Mice, Inbred C57BL , Mice, Transgenic , Picryl Chloride/adverse effects , Receptors, Tumor Necrosis Factor, Type I/genetics , Receptors, Tumor Necrosis Factor, Type I/physiology , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/physiology
13.
J Dtsch Dermatol Ges ; 7(8): 693-6, 2009 Aug.
Article in English, German | MEDLINE | ID: mdl-19243482

ABSTRACT

Subcorneal pustulosis (Sneddon-Wilkinson disease) is a rare inflammatory neutrophilic dermatosis. While subcorneal pustulosis is often associated with an IgA gammopathy, the combined lack of IgG/IgM seen in our case is rare. An 83-year-old man with combined lack of IgG/IgM and monoclonal gammopathy type IgA/Kappa presented with subcorneal pustules. Intravenous immunoglobulin therapy led to complete regression and might be another therapeutic option.


Subject(s)
IgG Deficiency/complications , IgG Deficiency/drug therapy , Immunoglobulins, Intravenous/administration & dosage , Paraproteinemias/complications , Paraproteinemias/drug therapy , Skin Diseases, Vesiculobullous/complications , Skin Diseases, Vesiculobullous/drug therapy , Aged, 80 and over , Humans , Immunologic Factors/administration & dosage , Male , Treatment Outcome
14.
Eur J Dermatol ; 18(6): 667-70, 2008.
Article in English | MEDLINE | ID: mdl-18955201

ABSTRACT

Chronic graft-versus-host disease (GVHD) is almost always associated with skin diseases appearing either as lichenoid GVHD, sclerodermatous GVHD (sGVHD) or as eosinophilic fasciitis-like disease. The two latter frequently result in severe and deep sclerosis. Immunosuppressive therapy is of little help in sclerodermatous or eosinophilic fasciitis-like types of GVHD. Based on data showing that PUVA-bath photochemotherapy is effective in the treatment of severe localized sclerosis of the skin, we investigated the efficacy of PUVA-bath photochemotherapy and isotretinoin in sGVHD. In a retrospective study we analyzed fourteen consecutive patients with sGVHD who received PUVA-bath photochemotherapy, five in combination with oral isotretinoin. Seven patients improved and four showed complete remission. Surprisingly, the therapy was complicated by the development of ulcers within the sclerotic plaques during the early periods of treatment. These ulcers cleared in most patients when PUVA-bath photochemotherapy was continued. Thus, PUVA-bath photochemotherapy alone or in combination with isotretinoin may resolve or improve GVHD associated sclerosis in selected patients.


Subject(s)
Dermatologic Agents/therapeutic use , Graft vs Host Disease/drug therapy , Isotretinoin/therapeutic use , PUVA Therapy , Adult , Baths , Chronic Disease , Graft vs Host Disease/pathology , Humans , Methoxsalen/administration & dosage , Middle Aged , Photosensitizing Agents/administration & dosage , Sclerosis , Skin/pathology
15.
Cancer Cell ; 13(6): 507-18, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18538734

ABSTRACT

Immune responses may arrest tumor growth by inducing tumor dormancy. The mechanisms leading to either tumor dormancy or promotion of multistage carcinogenesis by adaptive immunity are poorly characterized. Analyzing T antigen (Tag)-induced multistage carcinogenesis in pancreatic islets, we show that Tag-specific CD4+ T cells home selectively into the tumor microenvironment around the islets, where they either arrest or promote transition of dysplastic islets into islet carcinomas. Through combined TNFR1 signaling and IFN-gamma signaling, Tag-specific CD4+ T cells induce antiangiogenic chemokines and prevent alpha(v)beta(3) integrin expression, tumor angiogenesis, tumor cell proliferation, and multistage carcinogenesis, without destroying Tag-expressing islet cells. In the absence of either TNFR1 signaling or IFN-gamma signaling, the same T cells paradoxically promote angiogenesis and multistage carcinogenesis. Thus, tumor-specific T cells can directly survey multistage carcinogenesis through cytokine signaling.


Subject(s)
CD4-Positive T-Lymphocytes/immunology , Cell Proliferation , Cell Transformation, Neoplastic/immunology , Insulinoma/immunology , Interferon-gamma/metabolism , Pancreatic Neoplasms/immunology , Receptors, Tumor Necrosis Factor, Type I/metabolism , Signal Transduction , Animals , Antigens, Viral, Tumor/genetics , Antigens, Viral, Tumor/metabolism , Blood Glucose/metabolism , CD4-Positive T-Lymphocytes/metabolism , CD4-Positive T-Lymphocytes/pathology , CD4-Positive T-Lymphocytes/transplantation , Cell Movement , Cell Survival , Cell Transformation, Neoplastic/genetics , Cell Transformation, Neoplastic/metabolism , Cell Transformation, Neoplastic/pathology , Cells, Cultured , GTPase-Activating Proteins/genetics , GTPase-Activating Proteins/metabolism , Immunotherapy/methods , Insulinoma/blood supply , Insulinoma/genetics , Insulinoma/metabolism , Insulinoma/pathology , Insulinoma/therapy , Integrin alphaVbeta3/metabolism , Mice , Mice, Inbred C3H , Mice, Knockout , Mice, Transgenic , Neovascularization, Pathologic/immunology , Neovascularization, Pathologic/pathology , Pancreatic Neoplasms/blood supply , Pancreatic Neoplasms/genetics , Pancreatic Neoplasms/metabolism , Pancreatic Neoplasms/pathology , Pancreatic Neoplasms/therapy , Receptors, Tumor Necrosis Factor, Type I/deficiency , Receptors, Tumor Necrosis Factor, Type I/genetics , Th1 Cells/immunology , Th1 Cells/pathology , Time Factors , Whole-Body Irradiation
16.
J Cutan Pathol ; 35(10): 960-2, 2008 Oct.
Article in English | MEDLINE | ID: mdl-18494820

ABSTRACT

Lichen aureus is a rare disease of unknown origin that is classified under the group of pigmented purpuric dermatoses. Its most important differential diagnosis is both clinically and histologically mycosis fungoides, into which the disease can proceed in very rare cases. We describe an unusual multilocular lichen aureus possibly induced by the almost daily consumption of an energy drink. An 11-year-old boy presented with a history of asymptomatic ochre patches on his extremities and abdomen occurring after regular consumption of an energy drink. Histologic examination showed a band-like lymphocytic infiltrate, containing hemosiderin deposits and extravasal erythrocytes adjacent to dermal blood vessels, in the iron-stain detection of hemosiderin. Because of these findings, lichen aureus was diagnosed. After a 2-month abstention from the energy drink, no new lesions appeared and the present lesions grew pale and finally disappeared. The case shows a rare multilocular lichen aureus, which disappeared after the consumption of an energy drink was stopped. The ingredients of the energy drink are an example of a possible trigger of the disease.


Subject(s)
Beverages/adverse effects , Skin Diseases/etiology , Skin Diseases/immunology , Skin Diseases/pathology , T-Lymphocytes/immunology , Child , Clone Cells , Diagnosis, Differential , Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor , Hemosiderin/metabolism , Humans , Male , Mycosis Fungoides/pathology , Polymerase Chain Reaction
18.
J Invest Dermatol ; 126(2): 393-8, 2006 Feb.
Article in English | MEDLINE | ID: mdl-16374454

ABSTRACT

It is established that primary malignant melanomas (pMM) can be infiltrated by T-cell populations with predominantly one T-cell clone. As pMM generally express multiple tumor-associated antigens (TAA), here we used laser-capture microdissection (LCM) to isolate different tumor-infiltrating lymphocyte (TIL) clusters in order to determine whether pMM are infiltrated only by one single clone or whether the TAA may attract various T-cell populations. As T-cell receptor (TCR) clonality is a useful tool for the demonstration of specific T-cell clones, we analyzed 56 pMM, three cutaneous melanoma metastases, and 15 pairs of pMM with a sentinel lymph node (SLN) for clonal rearrangements of the (TCR) gamma chain gene. We detected the clonality of TCR gamma chain gene in 25 of 56 pMM, and in 10 of 17 SLN studied. In four of the 15 pairs of primary tumor and SLN, we found clonal TCR gamma in both the melanoma and the SLN, with two pairs harboring the identical clone. As we detected different clones in pMM and the corresponding SLN, we subsequently performed LCM in 21 malignant melanomas with multiple lymphocytic clusters for the presence of focal clonal T cells in different regions of the melanoma. In seven melanomas, both clusters of TILs showed the same rearranged TCR gamma chain gene and in five of the seven biopsies the clonal rearrangement occurred in different variable (V) regions of the TCR gamma chain gene. These tumors showed infiltration by more than one clone. In 10 biopsies TCR clonality was restricted to one cluster, while the second microdissected sample of the infiltrate was polyclonal. In conclusion, within one primary malignant melanoma several T-cell clones with different rearrangements may occur. The balance between these clones may decide on the progress of melanoma.


Subject(s)
Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor , Lymphocytes, Tumor-Infiltrating/immunology , Melanoma/immunology , Skin Neoplasms/immunology , T-Lymphocytes/immunology , Clone Cells , DNA, Neoplasm/analysis , Humans , Lasers , Lymphocytes, Tumor-Infiltrating/cytology , Melanoma/genetics , Microdissection , Neoplasm Staging , Receptors, Antigen, T-Cell, gamma-delta/genetics , Skin Neoplasms/genetics , T-Lymphocytes/cytology
19.
Am J Dermatopathol ; 27(3): 247-9, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15900132

ABSTRACT

Circumscribed palmar or plantar hypokeratosis is a new entity recently described by Perez et al in 2002. It seems to be underdiagnosed or clinically it is often misdiagnosed as Bowen's disease or porokeratosis. Obviously the number of case reports of circumscribed palmar or plantar hypokeratosis has increased since the first publication by Perez et al.The histopathological hallmarks of this condition are a stair-like configuration with an abrupt thinning of the stratum corneum from uninvolved to involved skin with a central hypokeratotic area. There are no atypical keratinocytes or cornoid lamellation. We describe two new patients with circumscribed palmar hypokeratosis. In one case there were additional histopathological features including the loss of granular cell layer in the center of the lesion and an overlying compact thin parakeratotic layer.


Subject(s)
Foot Dermatoses/pathology , Hand Dermatoses/pathology , Keratosis/pathology , Bowen's Disease/pathology , Diagnosis, Differential , Female , Humans , Middle Aged , Porokeratosis/pathology , Psoriasis/pathology
20.
Circulation ; 111(8): 1054-62, 2005 Mar 01.
Article in English | MEDLINE | ID: mdl-15723970

ABSTRACT

BACKGROUND: Bartonella species are the only known bacterial pathogens causing vasculoproliferative disorders in humans (bacillary angiomatosis [BA]). Cellular and bacterial pathogenetic mechanisms underlying the induction of BA are largely unknown. METHODS AND RESULTS: Activation of hypoxia-inducible factor-1 (HIF-1), the key transcription factor involved in angiogenesis, was detected in Bartonella henselae-infected host cells in vitro by immunofluorescence, Western blotting, electrophoretic mobility shift, and reporter gene assays and by immunohistochemistry in BA tissue lesions in vivo. Gene microarray analysis revealed that a B henselae infection resulted in the activation of genes typical for the cellular response to hypoxia. HIF-1 was essential for B henselae-induced expression of vascular endothelial growth factor as shown by inhibition with the use of HIF-1-specific short-interfering RNA. Moreover, infection with B henselae resulted in increased oxygen consumption, cellular hypoxia, and decreased ATP levels in host cells. Infection with a pilus-negative variant of B henselae did not lead to cellular hypoxia or activation of HIF-1 or vascular endothelial growth factor secretion, suggesting a crucial role of this bacterial surface protein in the angiogenic reprogramming of the host cells. CONCLUSIONS: B henselae induces a proangiogenic host cell response via HIF-1. Our data provide for the first time evidence that HIF-1 may play a role in bacterial infections.


Subject(s)
Angiomatosis, Bacillary/pathology , DNA-Binding Proteins/physiology , Nuclear Proteins/physiology , Transcription Factors/physiology , Adenosine Triphosphate/metabolism , Bartonella henselae/isolation & purification , Bartonella henselae/pathogenicity , Cell Hypoxia/physiology , DNA-Binding Proteins/immunology , DNA-Binding Proteins/metabolism , Endothelial Cells/microbiology , Endothelium, Vascular/cytology , Fimbriae, Bacterial/metabolism , Fimbriae, Bacterial/physiology , HeLa Cells/chemistry , HeLa Cells/metabolism , HeLa Cells/microbiology , Histiocytes/chemistry , Histiocytes/pathology , Humans , Hypoxia-Inducible Factor 1 , Hypoxia-Inducible Factor 1, alpha Subunit , Immunohistochemistry/methods , Macrophages/chemistry , Macrophages/pathology , Neovascularization, Pathologic/microbiology , Nuclear Proteins/immunology , Nuclear Proteins/metabolism , Transcription Factors/immunology , Transcription Factors/metabolism , Umbilical Veins/cytology , Up-Regulation/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...